CA-MARY-KAY
24.2.2021 14:36:06 CET | Business Wire | Press release
Glamhive announced its fourth online conference to be held on February 27, 2021. The Glamhive Digital Winter Style and Beauty Summit will bring together top fashion and beauty leaders, from Kristen Bell's stylist to billion-dollar founder-turned female founder investor Cindy Eckert. The innovative leaders will discuss fashion, beauty, entrepreneurship, and more. Stephanie Sprangers and Nicole Chavez will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005275/en/
"I have loved being part of Glamhive's style & beauty summits, particularly during this challenging time. The summits have brought a sense of community, which is lacking in the world of creative talent, plus I have made some amazing connections with other artists along the way," said Nicole Chavez, celebrity stylist. Nicole is one of the most in-demand stylists today. Her clientele has ranged from A-List stars Kristen Bell, Rachel Bilson, Jessica Simpson, Ellie Bamber, Scarlett Johansson, Catherine Zeta-Jones, and many more. Her work has been featured in many publications, including W, InStyle, and Harper's Bazaar.
"Glamhive's vision is to give the benefits of working with a personal stylist available to everyone, everywhere, and our digital events are a wonderful extension of that. The silver lining of the past year is that it enabled us to pivot our style summits to digital, thereby making it possible for everyone, everywhere to meet and learn from the best in the business," said Stephanie Sprangers, Glamhive Founder and CEO. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature over 60 speakers. Below is an overview of some of the topics that this all-star speaker line-up will cover.
TOPICS SNAPSHOT:
The day will consist of 22 segments across two-tracks. A snapshot:
- Red Carpet Style: Creating Iconic Style Moments
- 2021 Trends: Post-Pandemic Style
- Winning the Style Game: Vintage is Your Secret Weapon
- The Stylists Playbook: How to Get the Best Style of Your Life
- Beauty Boss Babe: An Interview with Jamie Kern Lima
- The Ultimate Guide to "Easy" Hair
- Let's Get Social: The Best Instagram and TikTok Beauty Trends
- The Astrology of Fashion: With Susan Miller
- More Than Meets the Eye: What Your Clothes Say About You
- The ROI of Style: How Dressing Well Pays Off
- How I Built This: Darn Good Advice from Women Who Made It to the Top
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Serena Williams, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr., Keanu Reeves, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, and more.
CELEBRITY STYLISTS:
Nicole Chavez, Jill + Jordan, Jeanne Yang, Jennifer Rade, Tara Swennen, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Kesha McLoud, and Sonia Young.
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Tommy Buckett, Todd Harris, Diana Madison, Danny Moon, AJ Crimson, and Helen Reavey.
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS:
Claire Sulmers (Fashion Bomb Daily), Hillary Kerr (WhoWhatWear), Tara Rudes Dann (L'Agence), Steven Dann (Designer), Cindy Eckert (The Pink Ceiling Fund), Helen Ravey (Act+Acre), Cassandra Cadwell (Violet Grey), Michelle Waugh (Designer), Clarissa Egana (Port De Bras), Amy Rosoff Davis (Celebrity Trainer), Jamie Kern Lima (IT Cosmetics).
MODERATORS:
Brian Underwood (O Magazine), Brooke Jaffe (Penske Media), Pandora Amoratis (Daily Mail), Andrea Lavanthal (PEOPLE), Robin Nazzaro (O Magazine), Alexis Bennett (Vogue) and Kibwe Chase-Marshall (The Kelly Initiative).
Tickets to the conference are $149 for an all-day ticket. The Glamhive Digital Winter Style and Beauty Summit's presenting sponsor is Mary Kay Inc. and its Mary Kay Global Design Studio.
For more information, visit www.glamhive.com/upcoming .
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. The Glamhive platform is a seamless end-to-end platform for stylists to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005275/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom